In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on Aerovate Therapeutics (AVTE – Research Report). The company’s shares closed last Friday at $19.63.
According to TipRanks, Thome is a 3-star analyst with an average return of 4.7% and a 50.00% success rate. Thome covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Axsome Therapeutics, and United Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aerovate Therapeutics with a $41.50 average price target.
See the top stocks recommended by analysts >>
Based on Aerovate Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $19.56 million. In comparison, last year the company had a GAAP net loss of $13.59 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aerovate Therapeutics (AVTE) Company Description:
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, a devastating disease impacting people in the United States and Europe.
